TABLE 1.
Demographics and baseline characteristics (n = 15)
| Demographics | |
| Gender Male Female |
10 5 |
| Median (range) age in years | 38 (23–69) |
| Race Caucasian Black |
14 1 |
| Performance status 0 1 2 |
5 9 1 |
| Original histology | |
| Astrocytoma WHO 2016 grade 2 WHO 2016 grade 3 |
4 5 |
| Glioblastoma WHO 2016 grade 4 |
3 |
| Oligodendroglioma WHO 2016 grade 2 WHO 2016 grade 3 |
2 1 |
| IDH mutation status IDH1 IDH2 |
13 2 |
| WHO 2021 grading | |
| Astrocytoma WHO 2021 grade 2 WHO 2021 grade 3 WHO 2021 grade 4 |
4 3 5 |
| Oligodendroglioma WHO 2021 grade 2 WHO 2021 grade 3 |
2 1 |
| Prior treatment | |
| Surgery Surgical resection Biopsy |
11 4 |
| Radiation Yes No Median (range) time in years from last radiation to olaparib initiation |
14 1 15.48 (0.59–10.59) |
| Prior chemotherapy | |
| Temozolomide Adjuvant Neoadjuvant |
13 10 9 |
| Procarbazine/Vincrinstine/Lomustine Adjuvant Neoadjuvant Bevacizumab Procarbazine/Lomustine Temozolomide/Bevacizumab/Lomustine Carboplatin/Etoposide |
3 1 2 2 1 1 1 |
| Prior immunotherapy | |
| Nivolumab | 2 |
|
Prior lines of chemotherapy/immunotherapy
1 2 3 4 |
5 5 3 2 |